Boehringer Ingelheim & Xencor Ink Biosuperiors Pact

Xencor and Boehringer Ingelheim have entered into a new alliance on the development of new biosuperior monoclonal antibodies.

Xencor, Inc. and Boehringer Ingelheim have entered a collaboration agreement for certain Xencor biosuperior monoclonal antibodies.

BI will provide all manufacturing and product supply from preclinical through Phase I development. Xencor is responsible for preclinical and clinical studies and retains all development and commercial rights to products. For clinical programs beyond Phase I, BI has certain manufacturing rights to supply clinical and commercial material to Xencor.

"Xencor has developed a deep portfolio of biosuperior antibodies with the potential for superior clinical and commercial performance, and this collaboration agreement with BI allows us to establish an important relationship with the leading global contract manufacturer of biologics," said Bas